| |
|
|
|
Xtalks, Online
2024-10-04
It is an exciting time for oncology drug development, characterized by rapid innovation and significant advancements in personalized medicine, and the landscape is witnessing a surge in clinical trials exploring novel mechanisms of action, biomarkers and combination therapies to overcome resistance and enhance efficacy.
What treatment modalities are healthcare providers (HCPs) most excited about? What groundbreaking research is piquing their interest? Are antibody-drug conjugates (ADCs) and theranostics — potentially transformative therapies getting the spotlight of late — living up to their hype?
These questions and more will be answered through a survey of HCPs attending the European Society for Medical Oncology (ESMO) annual meeting — one of the premier events in the oncology community, bringing together thousands of oncologists, researchers and healthcare professionals from around the world to share the latest scientific developments, research findings and clinical advancements in cancer treatment.
Join an engaging webinar that will unveil insights from oncologists surveyed at the ESMO 2024 conference. The expert speakers will identify and explore the data that oncologists consider most impactful from the conference and provide a closer look at the transformative potential of ADCs and theranostics. They will also examine the oncology drug development landscape, highlighting the surge in innovative trials and the strategic shifts in treatment approaches.
Register for this webinar to understand what treatment modalities and research are capturing the attention of oncologists and healthcare professionals in oncology drug development.
Keywords: Drug Development, Clinical Research, CRO, Oncology, Oncology Drugs, Oncology Trials, Oncology Clinical Trials, Therapeutic Areas, Oncology Drug Development, Cell & Gene Therapy
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Wouter Bartholomeus, MD, Executive Medical Director Oncology & Hematology, Syneos Health
Dr. Patrick Kelly, MD, Vice President, Medical Management, Oncology & Hematology, Syneos Health
Dr. Prateet Minhas, MD, Managing Director, Consulting, Syneos Health
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-04
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|